BR112017000955A2 - método para determinar tnfr2:fc, método de purificação de tnfr2:fc e composição de tnfr2:fc - Google Patents

método para determinar tnfr2:fc, método de purificação de tnfr2:fc e composição de tnfr2:fc

Info

Publication number
BR112017000955A2
BR112017000955A2 BR112017000955A BR112017000955A BR112017000955A2 BR 112017000955 A2 BR112017000955 A2 BR 112017000955A2 BR 112017000955 A BR112017000955 A BR 112017000955A BR 112017000955 A BR112017000955 A BR 112017000955A BR 112017000955 A2 BR112017000955 A2 BR 112017000955A2
Authority
BR
Brazil
Prior art keywords
tnfr2
determining
composition
purification
tfr2
Prior art date
Application number
BR112017000955A
Other languages
English (en)
Inventor
RUPPRECHTER Alfred
Posch Christoph
Toll Hansjörg
Holzmann Johann
Fuchs Michael
Mayer Robert
LAMANNA William
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51210344&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017000955(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of BR112017000955A2 publication Critical patent/BR112017000955A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
    • G01N21/33—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using ultraviolet light
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8831—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving peptides or proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/20—Post-translational modifications [PTMs] in chemical analysis of biological material formation of disulphide bridges

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente invenção é dirigida a métodos para determinar a quantidade relativa de tnfr2:fc em ponte de dissulfeto incorreta em uma amostra de tnfr2:fc, uma proteína de fusão que é usada em uma variedade de aplicações terapêuticas. além disso, a invenção refere-se a um método para a purificação de tnfr2:fc usando o dito método para determinar a porcentagem de tnfr2:fc em ponte de dissulfeto incorreta, e para composições tnfr2:fc obtidas desse modo.
BR112017000955A 2014-07-18 2015-07-17 método para determinar tnfr2:fc, método de purificação de tnfr2:fc e composição de tnfr2:fc BR112017000955A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14177696.3A EP2975050B1 (en) 2014-07-18 2014-07-18 Quantification of misfolded TNFR2:Fc
PCT/EP2015/066385 WO2016009036A1 (en) 2014-07-18 2015-07-17 Quantification of misfolded tnfr2:fc

Publications (1)

Publication Number Publication Date
BR112017000955A2 true BR112017000955A2 (pt) 2018-01-16

Family

ID=51210344

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017000955A BR112017000955A2 (pt) 2014-07-18 2015-07-17 método para determinar tnfr2:fc, método de purificação de tnfr2:fc e composição de tnfr2:fc

Country Status (10)

Country Link
US (2) US9598718B2 (pt)
EP (1) EP2975050B1 (pt)
KR (1) KR20170031145A (pt)
AU (1) AU2015289100B2 (pt)
BR (1) BR112017000955A2 (pt)
CA (1) CA2952342A1 (pt)
ES (1) ES2733298T3 (pt)
MX (1) MX2017000831A (pt)
RU (1) RU2698671C2 (pt)
WO (1) WO2016009036A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0611901A2 (pt) 2005-06-14 2012-08-28 Amgen, Inc composição, liofilizado, kit, e, processo para preparar uma composição
AU2017345490B2 (en) 2016-10-21 2022-07-07 Amgen Inc. Pharmaceutical formulations and methods of making the same
CA3233422A1 (en) * 2021-09-28 2023-04-06 Kashiv Biosciences, Llc An improved process for purification of fusion protein

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
WO2003102225A1 (en) * 2002-05-31 2003-12-11 Waters Investments Limited Destructible surfactants and uses thereof
AU2004262014B2 (en) 2003-08-01 2010-06-17 Amgen Inc. Crystalline tumor necrosis factor receptor 2 polypeptides
US7408030B2 (en) * 2005-01-13 2008-08-05 North Carolina State University Purification of immunoglobulins using affinity chromatography and peptide ligands
JP2010501623A (ja) * 2006-08-28 2010-01-21 アレス トレーディング ソシエテ アノニム Ｆｃ含有タンパク質の精製法
WO2010002911A2 (en) * 2008-06-30 2010-01-07 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods and materials for monitoring myeloma using quantitative mass spetrometry
RU2644651C2 (ru) 2010-04-26 2018-02-13 Новартис Аг Среда для культивирования клеток
SG185037A1 (en) 2010-04-26 2012-11-29 Novartis Ag Improved cell culture medium
CN102382190B (zh) 2010-09-01 2014-04-09 山东新时代药业有限公司 分离和去除TNFR-Fc融合蛋白中寡聚体的方法
AU2012220890A1 (en) * 2011-02-25 2013-08-29 Merck Sharp & Dohme Corp. Yeast strain for the production of proteins with modified O-glycosylation
EP2723759A4 (en) 2011-06-24 2015-01-28 Reddys Lab Ltd Dr PURIFICATION OF CHIMERIC PROTEIN
KR101454316B1 (ko) 2011-08-17 2014-10-27 한화케미칼 주식회사 활성형 ＴＮＦＲ-Ｆｃ 융합 단백질을 제조하는 방법
CN104902914B (zh) * 2012-09-11 2019-01-01 科荣生生物科学公司 高纯度和优异产量的正确折叠的依那西普
WO2014102814A1 (en) 2012-12-31 2014-07-03 Intas Biopharmaceuticals Limited Process for the purification of fc fusion proteins
ES2759061T3 (es) * 2013-03-15 2020-05-07 Biomolecular Holdings Llc Inmunoglobulina híbrida que contiene unión no peptidílica

Also Published As

Publication number Publication date
US20160017403A1 (en) 2016-01-21
EP2975050B1 (en) 2019-05-29
US9182410B1 (en) 2015-11-10
EP2975050A1 (en) 2016-01-20
AU2015289100A1 (en) 2017-01-12
US9598718B2 (en) 2017-03-21
AU2015289100B2 (en) 2019-08-15
MX2017000831A (es) 2017-05-01
ES2733298T3 (es) 2019-11-28
KR20170031145A (ko) 2017-03-20
WO2016009036A1 (en) 2016-01-21
RU2017102487A3 (pt) 2018-10-03
RU2017102487A (ru) 2018-08-20
RU2698671C2 (ru) 2019-08-28
CA2952342A1 (en) 2016-01-21

Similar Documents

Publication Publication Date Title
BR112018007017A2 (pt) polipeptídeos
CL2020003409A1 (es) Moléculas de unión específicas para cd73 y métodos de fabricación de las mismas (divisional de la solicitud no. 201701154)
CY1120390T1 (el) Συνθεση και μεθοδος για διαγνωση και θεραπεια ασθενειων που σχετιζονται με εκφυλισμο νευριτων
DK3019619T3 (da) Sammensætninger, der omfatter syntetiske polynukleotider, som koder for crispr-beslægtede proteiner, og syntetiske sgrna'er, og anvendelsesfremgangsmåder
CL2017001204A1 (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa
BR112017026330A2 (pt) molécula de ligação de lag-3 capaz de ligação tanto o lag-3 humano quanto ao lag-3 de macaco cynomolgus
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201691974A1 (ru) Антитела против ox40 и способы их применения
BR112017012615A2 (pt) composição e película de enrijecimento da pele, e, método para melhorar a aparência da pele.
CR20190330A (es) Anticuerpos anti-ox40 y sus usos
EA201591515A1 (ru) Полипептиды il-22, химерные белки il-22 fc и их применение
BR112017027567A2 (pt) proteínas de fusão para inibir a angiogênese
EA201890080A1 (ru) Анализ модуляторов
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201691610A8 (ru) Анти-jagged1 антитела и способы применения
BR112017013568A2 (pt) compostos bicíclicos fundidos para o tratamento de doenças
EA201691541A1 (ru) Новые анти-baff антитела
BR112017005266A2 (pt) inibidores de mk2 e uso dos mesmos
BR112016023851A2 (pt) ?composição de revestimento de duas partes e método para revestir uma superfície?
CR20170262A (es) Composiciones y métodos para anticuerpos dirigidos a bmp6
EA201792466A1 (ru) АНТИТЕЛА ПРОТИВ FcRn
EA202191513A1 (ru) Снижение вязкости фармацевтических составов
BR112016029013A2 (pt) aperfeiçoamento em composição nasal e método de utilização do mesmo
DK3247684T3 (da) Fremgangsmåder til fremstilling af amorfe hydrauliske silikatbindemidler med lavt calciumindhold
AR100944A1 (es) ANTICUERPOS ANTAGONISTAS DE INTERFERÓN a Y w

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]